Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1979 Jan;7(1):55-62.
doi: 10.1111/j.1365-2125.1979.tb00897.x.

Clonidine withdrawal. Mechanism and frequency of rebound hypertension

Clonidine withdrawal. Mechanism and frequency of rebound hypertension

G G Geyskes et al. Br J Clin Pharmacol. 1979 Jan.

Abstract

1. The frequency and pathophysiology of the clonidine withdrawal syndrome was studied in fourteen hypertensive patients on chronic clonidine therapy. 2. After sudden cessation of clonidine (900 microgram daily) almost all of the patients showed an excessive increase of the heart rate and blood pressure. Seven of the fourteen patients had subjective symptoms, in three severe enough to require interruption of observation by therapeutic intervention 12 to 60 h after the last dose of clonidine. After clonidine withdrawal, NAE increased to abnormally high values in correlation with the blood pressure (P less than 0.01) and heart rate (P less than 0.001), whereas PRA even decreased initially, probably secondary to the rise of the blood pressure, and only rose, although not significantly, 48 h after withdrawal. PRA was not correlated with NAE, heart rate, or blood pressure. 3. It is concluded that the clonidine withdrawal phenomenon is a frequently occurring and potentially dangerous syndrome. Overactivity of the sympathetic nervous system is mainly responsible, without the mediation of the renin angiotensin system. This also explains our experience that adrenergic beta-receptor blocking drugs do not prevent the rise in BP, although they alleviate some of the symptoms.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Pharmacol Exp Ther. 1962 Dec;138:360-75 - PubMed
    1. Lancet. 1977 Jun 4;1(8023):1171-4 - PubMed
    1. Mayo Clin Proc. 1977 Jun;52(6):395-8 - PubMed
    1. Postgrad Med J. 1976;52 Suppl 7:128-36 - PubMed
    1. Br Med J. 1976 Apr 17;1(6015):942-3 - PubMed